GRI Bio Inc (NASDAQ:GRI)’s traded shares stood at 3.76 million during the latest session, with the company’s beta value hitting -1.68. At the last check today, the stock’s price was $1.22, to imply a decrease of -11.96% or -$0.16 in intraday trading. The GRI share’s 52-week high remains $103.87, putting it -8413.93% down since that peak but still an impressive 9.84% since price per share fell to its 52-week low of $1.10.

GRI Bio Inc (NASDAQ:GRI) trade information

After registering a -11.96% downside in the latest session, GRI Bio Inc (GRI) has traded red over the past five days. The 5-day price performance for the stock is -16.21%, and -33.97% over 30 days. With these gigs, the year-to-date price performance is -91.37%.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 70.23% for the past 5-year period. While 2025 is set for a 94.36% return in earnings, projections for the next 5 years are at 82.63% annually.

GRI Dividends

GRI Bio Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund as the top two Mutual Funds with the largest holdings of the GRI Bio Inc (GRI) shares. Going by data provided on Mar 31, 2025 , Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 3.24 shares. This is just over 0.15% of the total shares, with a market valuation of $3983.0. Data from the same date shows that the other fund manager holds a little less at 757.0, or 0.04% of the shares, all valued at about 931.0.